XSHE300181
Market cap1.40bUSD
Jan 15, Last price
14.94CNY
1D
-0.60%
1Q
-3.61%
Jan 2017
63.64%
IPO
268.41%
Name
Zhejiang Jolly Pharmaceutical Co Ltd
Chart & Performance
Profile
Zhejiang Jolly Pharmaceutical Co., Ltd. engages in the research, production, and marketing of Chinese medicinal products in China and internationally. The company offers Wuling capsule that is used to treat insomnia, amnesia, heart palpitations, lack of energy, lassitude in loin and legs, and giddy tinnitus, as well as deficiency of energy and weak pulse caused by the disharmony of heart and kidney, or neurasthenia. It also provides Lingze tablet, which is used to treat frequent urination, dysuria, weak steam of urine, endless urine, and soreness and weakness of waist and knees caused by benign prostatic hyperplasia, kidney deficiency, and blood stasis; and Bailing tablet that is used as the adjuvant therapy to treat cough, asthma, back pain, and chronic bronchitis, which are caused by the deficiency of lungs and kidney. In addition, the company offers Linglianhua particles for the treatment of symptoms, including sweating, insomnia, dysphoria, heart palpitations, dreaminess, giddy tinnitus, lassitude in loin and legs, dry stool, and abnormal furred tongue, as well as weak pulse caused by perimenopausal syndrome, or disharmony of heart and kidney. Further, it provides azithromycin, clindamycin phosphate, doxapram, pefloxacin mesylate, adenosine cyclophosphate, and sodium nitroprusside injections. Additionally, the company offers materials, such as cordyceps cephalosporium, fermented cordyceps, and Wuling powders. It also invests and participates in the medical services of Deqing No.3 People's Hospital. The company was formerly known as Zhejiang Jolly Pharmaceutical Health Products Co., LTD. and changed its name to Zhejiang Jolly Pharmaceutical Co., Ltd. in 1998. Zhejiang Jolly Pharmaceutical Co., Ltd. was founded in 2000 and is based in Huzhou, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | 1,942,493 7.61% | 1,805,155 23.86% | |||||||
Cost of revenue | 1,433,726 | 1,464,376 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | 508,767 | 340,780 | |||||||
NOPBT Margin | 26.19% | 18.88% | |||||||
Operating Taxes | 55,879 | 38,603 | |||||||
Tax Rate | 10.98% | 11.33% | |||||||
NOPAT | 452,889 | 302,177 | |||||||
Net income | 382,936 40.27% | 273,007 52.17% | |||||||
Dividends | (219,955) | (121,725) | |||||||
Dividend yield | 2.96% | 1.63% | |||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
Debt | |||||||||
Debt current | 193,061 | 140,998 | |||||||
Long-term debt | 33,375 | 54,262 | |||||||
Deferred revenue | 19,897 | 19,757 | |||||||
Other long-term liabilities | 1 | ||||||||
Net debt | (885,243) | (1,279,174) | |||||||
Cash flow | |||||||||
Cash from operating activities | 288,461 | 318,591 | |||||||
CAPEX | (131,715) | ||||||||
Cash from investing activities | (263,576) | ||||||||
Cash from financing activities | (159,320) | 643,099 | |||||||
FCF | 180,134 | 125,066 | |||||||
Balance | |||||||||
Cash | 1,082,979 | 1,092,899 | |||||||
Long term investments | 28,700 | 381,535 | |||||||
Excess cash | 1,014,555 | 1,384,176 | |||||||
Stockholders' equity | 1,480,842 | 1,632,156 | |||||||
Invested Capital | 1,989,038 | 1,508,314 | |||||||
ROIC | 25.90% | 21.05% | |||||||
ROCE | 16.82% | 11.49% | |||||||
EV | |||||||||
Common stock shares outstanding | 696,247 | 701,387 | |||||||
Price | 10.66 -0.09% | 10.67 -8.49% | |||||||
Market cap | 7,421,998 -0.83% | 7,483,803 5.46% | |||||||
EV | 6,581,959 | 6,260,805 | |||||||
EBITDA | 573,688 | 401,288 | |||||||
EV/EBITDA | 11.47 | 15.60 | |||||||
Interest | 7,623 | 8,320 | |||||||
Interest/NOPBT | 1.50% | 2.44% |